JP2012519675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012519675A5 JP2012519675A5 JP2011552501A JP2011552501A JP2012519675A5 JP 2012519675 A5 JP2012519675 A5 JP 2012519675A5 JP 2011552501 A JP2011552501 A JP 2011552501A JP 2011552501 A JP2011552501 A JP 2011552501A JP 2012519675 A5 JP2012519675 A5 JP 2012519675A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- additive
- opioid analgesic
- fentanyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 22
- 239000000654 additive Substances 0.000 claims 6
- 230000000996 additive effect Effects 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- -1 methopone Chemical compound 0.000 claims 5
- 239000000014 opioid analgesic Substances 0.000 claims 5
- 229960002428 fentanyl Drugs 0.000 claims 4
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 4
- 239000010408 film Substances 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 229910010293 ceramic material Inorganic materials 0.000 claims 3
- 239000011148 porous material Substances 0.000 claims 3
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims 2
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims 2
- DEXMFYZAHXMZNM-UHFFFAOYSA-N Narceine Chemical compound OC(=O)C1=C(OC)C(OC)=CC=C1C(=O)CC1=C(CCN(C)C)C=C(OCO2)C2=C1OC DEXMFYZAHXMZNM-UHFFFAOYSA-N 0.000 claims 2
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 claims 2
- 229960001391 alfentanil Drugs 0.000 claims 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 2
- 229960001736 buprenorphine Drugs 0.000 claims 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 2
- 229960004193 dextropropoxyphene Drugs 0.000 claims 2
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims 2
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 claims 2
- 229960000920 dihydrocodeine Drugs 0.000 claims 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 238000005453 pelletization Methods 0.000 claims 2
- 229960000482 pethidine Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229960003394 remifentanil Drugs 0.000 claims 2
- 229960004739 sufentanil Drugs 0.000 claims 2
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims 2
- YQYVFVRQLZMJKJ-JBBXEZCESA-N (+)-cyclazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CC1CC1 YQYVFVRQLZMJKJ-JBBXEZCESA-N 0.000 claims 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 1
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 claims 1
- LLSKXGRDUPMXLC-UHFFFAOYSA-N 1-phenylpiperidine Chemical compound C1CCCCN1C1=CC=CC=C1 LLSKXGRDUPMXLC-UHFFFAOYSA-N 0.000 claims 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- KISZTEOELCMZPY-UHFFFAOYSA-N 3,3-diphenylpropylamine Chemical class C=1C=CC=CC=1C(CCN)C1=CC=CC=C1 KISZTEOELCMZPY-UHFFFAOYSA-N 0.000 claims 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 1
- 238000005698 Diels-Alder reaction Methods 0.000 claims 1
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 claims 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims 1
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 claims 1
- OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- ALFGKMXHOUSVAD-UHFFFAOYSA-N Ketobemidone Chemical compound C=1C=CC(O)=CC=1C1(C(=O)CC)CCN(C)CC1 ALFGKMXHOUSVAD-UHFFFAOYSA-N 0.000 claims 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 claims 1
- ONBWJWYUHXVEJS-ZTYRTETDSA-N Normorphine Chemical compound C([C@@H](NCC1)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ONBWJWYUHXVEJS-ZTYRTETDSA-N 0.000 claims 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- HPTYUNKZVDYXLP-UHFFFAOYSA-N aluminum;trihydroxy(trihydroxysilyloxy)silane;hydrate Chemical compound O.[Al].[Al].O[Si](O)(O)O[Si](O)(O)O HPTYUNKZVDYXLP-UHFFFAOYSA-N 0.000 claims 1
- 229960002512 anileridine Drugs 0.000 claims 1
- LKYQLAWMNBFNJT-UHFFFAOYSA-N anileridine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC1=CC=C(N)C=C1 LKYQLAWMNBFNJT-UHFFFAOYSA-N 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- RDJGWRFTDZZXSM-RNWLQCGYSA-N benzylmorphine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCC1=CC=CC=C1 RDJGWRFTDZZXSM-RNWLQCGYSA-N 0.000 claims 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims 1
- 229960001113 butorphanol Drugs 0.000 claims 1
- XFWJKVMFIVXPKK-UHFFFAOYSA-N calcium;oxido(oxo)alumane Chemical compound [Ca+2].[O-][Al]=O.[O-][Al]=O XFWJKVMFIVXPKK-UHFFFAOYSA-N 0.000 claims 1
- GPZLDQAEBHTMPG-UHFFFAOYSA-N clonitazene Chemical compound N=1C2=CC([N+]([O-])=O)=CC=C2N(CCN(CC)CC)C=1CC1=CC=C(Cl)C=C1 GPZLDQAEBHTMPG-UHFFFAOYSA-N 0.000 claims 1
- 229950001604 clonitazene Drugs 0.000 claims 1
- 229960004126 codeine Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 229950002213 cyclazocine Drugs 0.000 claims 1
- 229960001985 dextromethorphan Drugs 0.000 claims 1
- INUNXTSAACVKJS-OAQYLSRUSA-N dextromoramide Chemical compound C([C@@H](C)C(C(=O)N1CCCC1)(C=1C=CC=CC=1)C=1C=CC=CC=1)N1CCOCC1 INUNXTSAACVKJS-OAQYLSRUSA-N 0.000 claims 1
- 229960003701 dextromoramide Drugs 0.000 claims 1
- 229960003461 dezocine Drugs 0.000 claims 1
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- HDRXZJPWHTXQRI-BHDTVMLSSA-N diltiazem hydrochloride Chemical compound [Cl-].C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CC[NH+](C)C)C2=CC=CC=C2S1 HDRXZJPWHTXQRI-BHDTVMLSSA-N 0.000 claims 1
- RHUWRJWFHUKVED-UHFFFAOYSA-N dimenoxadol Chemical compound C=1C=CC=CC=1C(C(=O)OCCN(C)C)(OCC)C1=CC=CC=C1 RHUWRJWFHUKVED-UHFFFAOYSA-N 0.000 claims 1
- 229950011187 dimenoxadol Drugs 0.000 claims 1
- QIRAYNIFEOXSPW-UHFFFAOYSA-N dimepheptanol Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(O)CC)C1=CC=CC=C1 QIRAYNIFEOXSPW-UHFFFAOYSA-N 0.000 claims 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 claims 1
- 229960004192 diphenoxylate Drugs 0.000 claims 1
- SVDHSZFEQYXRDC-UHFFFAOYSA-N dipipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCCCC1 SVDHSZFEQYXRDC-UHFFFAOYSA-N 0.000 claims 1
- 229960002500 dipipanone Drugs 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- ZOWQTJXNFTWSCS-IAQYHMDHSA-N eptazocine Chemical compound C1N(C)CC[C@@]2(C)C3=CC(O)=CC=C3C[C@@H]1C2 ZOWQTJXNFTWSCS-IAQYHMDHSA-N 0.000 claims 1
- 229950010920 eptazocine Drugs 0.000 claims 1
- 229960004578 ethylmorphine Drugs 0.000 claims 1
- 229950004155 etorphine Drugs 0.000 claims 1
- CAHCBJPUTCKATP-FAWZKKEFSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 claims 1
- 238000001125 extrusion Methods 0.000 claims 1
- 229920000876 geopolymer Polymers 0.000 claims 1
- 229910052621 halloysite Inorganic materials 0.000 claims 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 1
- 229960000240 hydrocodone Drugs 0.000 claims 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 1
- 229960001410 hydromorphone Drugs 0.000 claims 1
- IFKPLJWIEQBPGG-UHFFFAOYSA-N isomethadone Chemical compound C=1C=CC=CC=1C(C(C)CN(C)C)(C(=O)CC)C1=CC=CC=C1 IFKPLJWIEQBPGG-UHFFFAOYSA-N 0.000 claims 1
- 229950009272 isomethadone Drugs 0.000 claims 1
- 229960003029 ketobemidone Drugs 0.000 claims 1
- 229960003406 levorphanol Drugs 0.000 claims 1
- IMYHGORQCPYVBZ-NLFFAJNJSA-N lofentanil Chemical compound CCC(=O)N([C@@]1([C@@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 IMYHGORQCPYVBZ-NLFFAJNJSA-N 0.000 claims 1
- 229950010274 lofentanil Drugs 0.000 claims 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 claims 1
- 229960001571 loperamide Drugs 0.000 claims 1
- FQXXSQDCDRQNQE-UHFFFAOYSA-N markiertes Thebain Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(OC)C5=C4C23C1O5 FQXXSQDCDRQNQE-UHFFFAOYSA-N 0.000 claims 1
- JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 claims 1
- 229960000365 meptazinol Drugs 0.000 claims 1
- YGSVZRIZCHZUHB-COLVAYQJSA-N metazocine Chemical compound C1C2=CC=C(O)C=C2[C@]2(C)CCN(C)[C@@]1([H])[C@@H]2C YGSVZRIZCHZUHB-COLVAYQJSA-N 0.000 claims 1
- 229950009131 metazocine Drugs 0.000 claims 1
- 125000005395 methacrylic acid group Chemical group 0.000 claims 1
- 229960001797 methadone Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- INAXVFBXDYWQFN-XHSDSOJGSA-N morphinan Chemical class C1C2=CC=CC=C2[C@]23CCCC[C@H]3[C@@H]1NCC2 INAXVFBXDYWQFN-XHSDSOJGSA-N 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 229960000805 nalbuphine Drugs 0.000 claims 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 claims 1
- 229960000938 nalorphine Drugs 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- HNDXBGYRMHRUFN-CIVUWBIHSA-N nicomorphine Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)OC(=O)C=4C=NC=CC=4)O[C@@H]1[C@]52CCN3C)C(=O)C1=CC=CN=C1 HNDXBGYRMHRUFN-CIVUWBIHSA-N 0.000 claims 1
- 229960004300 nicomorphine Drugs 0.000 claims 1
- 229950006134 normorphine Drugs 0.000 claims 1
- WCDSHELZWCOTMI-UHFFFAOYSA-N norpipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CCN1CCCCC1 WCDSHELZWCOTMI-UHFFFAOYSA-N 0.000 claims 1
- 229950007418 norpipanone Drugs 0.000 claims 1
- 229960002085 oxycodone Drugs 0.000 claims 1
- 229960005118 oxymorphone Drugs 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 claims 1
- 229960005301 pentazocine Drugs 0.000 claims 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims 1
- LOXCOAXRHYDLOW-UHFFFAOYSA-N phenadoxone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCOCC1 LOXCOAXRHYDLOW-UHFFFAOYSA-N 0.000 claims 1
- 229950004540 phenadoxone Drugs 0.000 claims 1
- 229960004315 phenoperidine Drugs 0.000 claims 1
- IPOPQVVNCFQFRK-UHFFFAOYSA-N phenoperidine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(O)C1=CC=CC=C1 IPOPQVVNCFQFRK-UHFFFAOYSA-N 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- ZBAFFZBKCMWUHM-UHFFFAOYSA-N propiram Chemical compound C=1C=CC=NC=1N(C(=O)CC)C(C)CN1CCCCC1 ZBAFFZBKCMWUHM-UHFFFAOYSA-N 0.000 claims 1
- 229950003779 propiram Drugs 0.000 claims 1
- 229950011009 racemorphan Drugs 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229930003945 thebaine Natural products 0.000 claims 1
- FQXXSQDCDRQNQE-VMDGZTHMSA-N thebaine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(OC)C5=C4[C@@]21[C@H]3O5 FQXXSQDCDRQNQE-VMDGZTHMSA-N 0.000 claims 1
- 239000010409 thin film Substances 0.000 claims 1
- 229960004380 tramadol Drugs 0.000 claims 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2009000592 | 2009-03-04 | ||
| GBPCT/GB2009/000592 | 2009-03-04 | ||
| PCT/GB2010/000374 WO2010100414A1 (en) | 2009-03-04 | 2010-03-02 | Abuse resistant formulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012519675A JP2012519675A (ja) | 2012-08-30 |
| JP2012519675A5 true JP2012519675A5 (enExample) | 2013-04-11 |
| JP5728705B2 JP5728705B2 (ja) | 2015-06-03 |
Family
ID=40823586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011552501A Active JP5728705B2 (ja) | 2009-03-04 | 2010-03-02 | 薬物乱用抵抗性製剤 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9622972B2 (enExample) |
| EP (1) | EP2403482B1 (enExample) |
| JP (1) | JP5728705B2 (enExample) |
| KR (1) | KR101751906B1 (enExample) |
| CN (1) | CN102341096B (enExample) |
| AU (1) | AU2010219449B2 (enExample) |
| BR (1) | BRPI1009121A2 (enExample) |
| CA (1) | CA2753664C (enExample) |
| DK (1) | DK2403482T3 (enExample) |
| EA (1) | EA031154B1 (enExample) |
| ES (1) | ES2660674T3 (enExample) |
| IL (1) | IL214583A (enExample) |
| MX (1) | MX336355B (enExample) |
| NO (1) | NO2403482T3 (enExample) |
| NZ (1) | NZ594513A (enExample) |
| PL (1) | PL2403482T3 (enExample) |
| WO (1) | WO2010100414A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010089132A1 (en) | 2009-02-06 | 2010-08-12 | Egalet A/S | Immediate release composition resistant to abuse by intake of alcohol |
| CA2766179A1 (en) | 2009-06-24 | 2010-12-29 | Egalet Ltd. | Controlled release formulations |
| NZ599594A (en) | 2009-10-30 | 2014-06-27 | Ix Biopharma Ltd | Fast dissolving solid dosage form |
| US12186426B2 (en) | 2009-10-30 | 2025-01-07 | Ix Biopharma Ltd. | Solid dosage form |
| RU2018141241A (ru) * | 2012-11-30 | 2019-01-24 | Экьюра Фармасьютикалз, Инк. | Саморегулируемое высвобождение фармацевтического ингредиента |
| US10420729B2 (en) * | 2013-03-15 | 2019-09-24 | R.P. Scherer Technologies, Llc | Abuse resistant capsule |
| JP6539274B2 (ja) | 2013-08-12 | 2019-07-03 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド | 押出成形された即放性乱用抑止性丸剤 |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| US20160106737A1 (en) | 2014-10-20 | 2016-04-21 | Pharmaceutical Manufacturing Research Services, Inc. | Extended Release Abuse Deterrent Liquid Fill Dosage Form |
| CA2936740C (en) | 2014-10-31 | 2017-10-10 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| GB201502073D0 (en) | 2015-02-09 | 2015-03-25 | Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd | HDEG technology |
| WO2016140961A1 (en) | 2015-03-02 | 2016-09-09 | Mc10, Inc. | Perspiration sensor |
| US20190046743A1 (en) * | 2016-02-29 | 2019-02-14 | Emplicure Ab | Devices for evaporation and inhalation of nicotine |
| EP3210596A1 (en) * | 2016-02-29 | 2017-08-30 | G.L. Pharma GmbH | Abuse-deterrent pharmaceutical composition |
| CN105769798A (zh) * | 2016-05-16 | 2016-07-20 | 张阳 | 一种高血压治疗药物的制备方法 |
| CN105997907A (zh) * | 2016-05-16 | 2016-10-12 | 胡小丽 | 高血压治疗药丸 |
| CN105997915A (zh) * | 2016-05-16 | 2016-10-12 | 张阳 | 一种高血压治疗用缓释片剂 |
| US9650338B1 (en) | 2016-07-29 | 2017-05-16 | VDM Biochemicals, Inc. | Opioid antagonist compounds and methods of making and using |
| GB201714412D0 (en) * | 2017-09-07 | 2017-10-25 | Emplicure Ab | Evaporation devices containing plant material |
| CN108720990A (zh) * | 2018-06-04 | 2018-11-02 | 界首市龙鑫生物科技有限公司 | 一种能够加快伤口愈合的医用冷敷贴 |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
| US20250228771A1 (en) * | 2022-04-01 | 2025-07-17 | EMPLICURE AB (publ) | Alkaline intraoral products |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE93384T1 (de) | 1983-11-14 | 1993-09-15 | Univ Kentucky Res Found | Poroese mikrokugeln zur arzneistoffabgabe sowie verfahren zu deren herstellung. |
| ATE71293T1 (de) * | 1986-09-18 | 1992-01-15 | London Pharmacy Innovation | Arzneiformulierung. |
| IT1197316B (it) | 1986-10-01 | 1988-11-30 | Proter Spa | Formulazione galenica ad uso orale di derivati della reina a lento rilascio per impiego terapeutico |
| JP2702953B2 (ja) | 1988-01-30 | 1998-01-26 | オリンパス光学工業株式会社 | 薬液含浸セラミックス |
| IT1216570B (it) | 1988-04-08 | 1990-03-08 | Vectorpharma Int | Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione. |
| JPH0230988A (ja) | 1988-07-20 | 1990-02-01 | Toshiba Corp | 宇宙軌道上発電プラント |
| JPH02268104A (ja) | 1989-04-07 | 1990-11-01 | Kanebo Ltd | 抗菌性組成物 |
| US5443812A (en) | 1989-04-24 | 1995-08-22 | Kanebo Ltd. | Stabilized synthetic zeolite and a process for the preparation thereof |
| JPH07188000A (ja) | 1993-12-27 | 1995-07-25 | Bridgestone Corp | 薬用被覆材 |
| JPH0930988A (ja) | 1995-07-21 | 1997-02-04 | Sumitomo Osaka Cement Co Ltd | 薬剤徐放性多孔質セラミックス成形体及びその製造方法 |
| GB2307862A (en) | 1995-12-05 | 1997-06-11 | David Jehan | Patch structures for transdermal therapy |
| WO1998023556A1 (en) | 1996-11-25 | 1998-06-04 | Kabushiki Kaisya Advance | Method of production of ceramics |
| US5902591A (en) | 1997-04-03 | 1999-05-11 | La Prairie Sa | Stable topical cosmetic/pharmaceutical emulsion compositions containing ascorbic acid |
| US6503231B1 (en) | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
| US6123925A (en) | 1998-07-27 | 2000-09-26 | Healthshield Technologies L.L.C. | Antibiotic toothpaste |
| US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| US6635281B2 (en) | 1998-12-23 | 2003-10-21 | Alza Corporation | Gastric retaining oral liquid dosage form |
| US20030118641A1 (en) | 2000-07-27 | 2003-06-26 | Roxane Laboratories, Inc. | Abuse-resistant sustained-release opioid formulation |
| AUPQ573300A0 (en) | 2000-02-21 | 2000-03-16 | Australian Nuclear Science & Technology Organisation | Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use |
| WO2001072663A2 (en) | 2000-03-24 | 2001-10-04 | Lyles Mark B | High density porous materials |
| CZ301790B6 (cs) | 2000-04-11 | 2010-06-23 | Sankyo Company Limited | Farmaceutický prípravek obsahující blokátor vápníku |
| US20020122828A1 (en) | 2001-03-02 | 2002-09-05 | Jun Liu | Hybrid porous materials for controlled release |
| MXPA03008057A (es) * | 2001-03-05 | 2004-10-15 | Johnson & Johnson | Composiciones farmaceuticas con sabor oculto. |
| DE60238422D1 (de) | 2001-09-24 | 2011-01-05 | Boston Scient Ltd | Optimierte dosierung bei paclitaxelhaltigen stents |
| JP5041651B2 (ja) | 2001-09-28 | 2012-10-03 | ティーエヌティーギャンブル・インコーポレーテッド | 生物体成分の送達系 |
| AU2002350207A1 (en) | 2001-11-19 | 2003-06-10 | Control Delivery Systems, Inc. | Topical delivery of codrugs |
| EP1513507B1 (en) | 2002-04-23 | 2011-03-16 | Durect Corporation | Transdermal analgesic systems with reduced abuse potential |
| WO2003092785A1 (en) | 2002-04-30 | 2003-11-13 | Morteza Shirkhanzadeh | Arrays of microneedles comprising porous calcium phosphate coating and bioactive agents |
| US8062573B2 (en) | 2002-09-16 | 2011-11-22 | Theraject, Inc. | Solid micro-perforators and methods of use |
| SE524334C2 (sv) | 2002-09-30 | 2004-07-27 | Cerbio Tech Ab | Värmegenererande biokompatibla keramiska material och förfarande för dess framställning |
| SE525236C2 (sv) | 2002-10-31 | 2005-01-11 | Cerbio Tech Ab | Förfarande för framställning av strukturerade keramiska beläggningar och belagda anordningar framställda med detta förfarande |
| SE524494C2 (sv) | 2002-12-31 | 2004-08-17 | Doxa Ab | Kemiskt bundna biomaterialelement med skräddarsydda egenskaper |
| CN1859906A (zh) | 2003-10-15 | 2006-11-08 | 株式会社纳米卵 | 含有多价金属无机盐包覆的视黄酸纳米颗粒的组合物 |
| WO2005039508A1 (en) | 2003-10-29 | 2005-05-06 | Doxa Ab | A two-step system for improved initial and final characteristics of a biomaterial |
| US20050181049A1 (en) | 2003-11-19 | 2005-08-18 | Dong Liang C. | Composition and method for enhancing bioavailability |
| WO2005065319A2 (en) | 2003-12-31 | 2005-07-21 | Cima Labs Inc. | Generally linear effervescent oral fentanyl dosage form and methods of administering |
| JP4832082B2 (ja) | 2004-02-03 | 2011-12-07 | 久光製薬株式会社 | 経皮薬物投与装置用インタフェース |
| US7315758B2 (en) | 2004-06-03 | 2008-01-01 | Lynntech, Inc. | Transdermal delivery of therapeutic agent |
| US20060016578A1 (en) * | 2004-06-24 | 2006-01-26 | Shine Ying Co., Ltd. | [high-performance two-phase flow evaporator] |
| CN1976751A (zh) | 2004-06-28 | 2007-06-06 | H.隆德贝克有限公司 | 释放化学物质的多孔物品 |
| AU2005271781A1 (en) | 2004-07-13 | 2006-02-16 | Altairnano, Inc. | Ceramic structures for prevention of drug diversion |
| EP1773264A1 (en) | 2004-07-13 | 2007-04-18 | Altairnano, Inc | Ceramic structures for controlled release of drugs |
| WO2006015299A2 (en) | 2004-07-30 | 2006-02-09 | Microchips, Inc. | Multi-reservoir device for transdermal drug delivery and sensing |
| JP2008510000A (ja) | 2004-08-19 | 2008-04-03 | アルザ・コーポレーシヨン | 制御放出性ナノ粒子有効薬剤配合物投与剤型品および方法 |
| US8535702B2 (en) | 2005-02-01 | 2013-09-17 | Boston Scientific Scimed, Inc. | Medical devices having porous polymeric regions for controlled drug delivery and regulated biocompatibility |
| FR2881652B1 (fr) | 2005-02-08 | 2007-05-25 | Flamel Technologies Sa | Forme pharmaceutique orale microparticulaire anti-mesuage |
| CA2599951A1 (en) | 2005-03-04 | 2006-09-14 | Altairnano, Inc. | Ceramic structures for controlled release of biologically active substances |
| DE102005040429A1 (de) | 2005-08-25 | 2007-03-01 | Heraeus Kulzer Gmbh | Wirkstofffreisetzungssystem und seine Verwendung |
| US8652529B2 (en) | 2005-11-10 | 2014-02-18 | Flamel Technologies | Anti-misuse microparticulate oral pharmaceutical form |
| US7682445B2 (en) | 2005-12-08 | 2010-03-23 | Doxa Ab | Powdered CBC system with improved reaction feature |
| EP1971351A2 (en) | 2005-12-29 | 2008-09-24 | Robert Basic | Mineral-herbal preparation consisting of zeolite and astragalus membranaceus root extract to treat allergies |
| US20070212414A1 (en) | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
| US20070248656A1 (en) | 2006-04-25 | 2007-10-25 | Galer Bradley S | Topical preparation dispensers and methods of using the same |
| US9023400B2 (en) | 2006-05-24 | 2015-05-05 | Flamel Technologies | Prolonged-release multimicroparticulate oral pharmaceutical form |
| DE102006028781A1 (de) | 2006-06-23 | 2007-12-27 | Robert Bosch Gmbh | Verfahren zur Herstellung von porösen Mikronadeln und ihre Verwendung |
| US20080214987A1 (en) | 2006-12-22 | 2008-09-04 | Nanomed Devices, Inc. | Microdevice And Method For Transdermal Delivery And Sampling Of Active Substances |
| EP2131878A4 (en) | 2007-03-01 | 2012-12-26 | Doxa Ab | INJECTABLE CEMENT COMPOSITION FOR ORTHOPEDIC AND DENTAL PURPOSES |
| WO2008105737A1 (en) | 2007-03-01 | 2008-09-04 | Doxa Ab | Stable cement composition for orthopaedic and dental use |
| US8778377B2 (en) | 2007-03-01 | 2014-07-15 | Doxa Ab | Drug implant carrier for drug delivery |
| EP2139531A4 (en) | 2007-03-28 | 2013-01-09 | Doxa Ab | CARRIER FOR DRUG DISPENSING |
| CN101104080B (zh) | 2007-04-24 | 2011-06-22 | 深圳市鸿华投资有限公司 | 沸石止血敷料及其制备方法和用途 |
| GB0709541D0 (en) | 2007-05-17 | 2007-06-27 | Jagotec Ag | Pharmaceutical excipient |
| EP2100850A1 (en) | 2008-03-11 | 2009-09-16 | Stichting Voor De Technische Wetenschappen | Microneedle array and a method for manufacturing microneedles |
| WO2010096704A2 (en) | 2009-02-19 | 2010-08-26 | Alex Garfield Bonner | Porous interpenetrating polymer network |
-
2010
- 2010-03-02 MX MX2011009214A patent/MX336355B/es unknown
- 2010-03-02 CN CN201080010486.7A patent/CN102341096B/zh not_active Expired - Fee Related
- 2010-03-02 EP EP10711246.8A patent/EP2403482B1/en active Active
- 2010-03-02 ES ES10711246.8T patent/ES2660674T3/es active Active
- 2010-03-02 WO PCT/GB2010/000374 patent/WO2010100414A1/en not_active Ceased
- 2010-03-02 EA EA201101281A patent/EA031154B1/ru not_active IP Right Cessation
- 2010-03-02 BR BRPI1009121A patent/BRPI1009121A2/pt not_active Application Discontinuation
- 2010-03-02 US US13/254,724 patent/US9622972B2/en active Active
- 2010-03-02 JP JP2011552501A patent/JP5728705B2/ja active Active
- 2010-03-02 AU AU2010219449A patent/AU2010219449B2/en not_active Ceased
- 2010-03-02 PL PL10711246T patent/PL2403482T3/pl unknown
- 2010-03-02 CA CA2753664A patent/CA2753664C/en active Active
- 2010-03-02 DK DK10711246.8T patent/DK2403482T3/en active
- 2010-03-02 KR KR1020117020752A patent/KR101751906B1/ko not_active Expired - Fee Related
- 2010-03-02 NZ NZ594513A patent/NZ594513A/xx not_active IP Right Cessation
- 2010-03-02 NO NO10711246A patent/NO2403482T3/no unknown
-
2011
- 2011-08-10 IL IL214583A patent/IL214583A/en active IP Right Grant
-
2017
- 2017-03-09 US US15/454,858 patent/US10543203B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012519675A5 (enExample) | ||
| HRP20150835T1 (hr) | Farmaceutski oblici doziranja s kontroliranim oslobađanjem | |
| JP2011126895A5 (enExample) | ||
| HRP20120641T1 (hr) | Oralni farmaceutski oblici doziranja otporni na neovlašteno korištenje koji sadrže opioidni analgetik | |
| JP2008534564A5 (enExample) | ||
| JP2014510094A5 (enExample) | ||
| JP2010511683A5 (enExample) | ||
| HRP20151189T1 (hr) | Produkti za dostavu opioida otporni na neovlašteno rukovanje | |
| JP2010189403A5 (enExample) | ||
| JP2024015430A5 (enExample) | ||
| JP2006524261A5 (enExample) | ||
| CA2519556A1 (en) | Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same | |
| JP2009529046A5 (enExample) | ||
| RU2007139827A (ru) | Фармацевтические композиции для лечения боли | |
| SI1551372T1 (en) | SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES | |
| JP2006524249A5 (enExample) | ||
| RU2010106202A (ru) | Составы неопиоидных и ограниченных опиоидных аналгетиков | |
| RU2017112301A (ru) | Стойкие к злоупотреблению фармацевтические композиции | |
| JP2009541320A5 (enExample) | ||
| RU2009101082A (ru) | Фармацевтические композиции | |
| JP2014088422A5 (enExample) | ||
| JP2011515495A5 (enExample) | ||
| RU2011135568A (ru) | Защищенная от применения не по назначению экструдированная из расплава композиция с уменьшенным взаимодействием со спиртом | |
| JP2010501543A5 (enExample) | ||
| RU2009141615A (ru) | Композиции и способы профилактики и лечения зависимости |